Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 201–300 of 1,676
HDL and cardiovascular disease
Nicholls, S. J., & Nelson, A. J. (2019) · Pathology · doi:10.1016/j.pathol.2018.10.017 · Cited by 118
Soria-Florido, M. T., Schröder, H., Grau, M., Fitó, M., & Lassale, C. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.04.015 · Cited by 99
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease
Shapiro, M. D., & Fazio, S. (2017) · F1000Research · doi:10.12688/f1000research.9845.1 · Cited by 97
Current therapies for lowering lipoprotein (a)
van Capelleveen, J. C., van der Valk, F. M., & Stroes, E. G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r053066 · Cited by 97
“(25) The larger ‘Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events’ (HPS2-THRIVE) had a similar approach and enrolled 25,773 high risk patients with prior cardiovascular disease who were randomized to receive extended release niacin in combination with laropiprant or placebo, on top…”
BackgroundResultInfluentialFerrari, R., Aguiar, C., Alegria, E., Bonadonna, R. C., Cosentino, F., Elisaf, M., Farnier, M., Ferrières, J., Filardi, P. P., Hancu, N., et al. (2016) · European Heart Journal Supplements · doi:10.1093/eurheartj/suw009 · Cited by 97
“statins alone and increased the risk of serious adverse events.(25) Historical data and the Figure 3 Global approach to cardiovascular risk taken by the experts.”
BackgroundBartlett, J., Predazzi, I. M., Williams, S. M., Bush, W. S., Kim, Y., Havas, S., Toth, P. P., Fazio, S., & Miller, M. (2016) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002436 · Cited by 96
Beginning to Understand High-Density Lipoproteins
Santos‐Gallego, C. G., Badimon, J. J., & Rosenson, R. S. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.001 · Cited by 100
Role of Niacin in Current Clinical Practice: A Systematic Review
Garg, A., Sharma, A., Krishnamoorthy, P. M., Garg, J., Virmani, D., Sharma, T., Stefanini, G. G., Kostis, J. B., Mukherjee, D., & Sikorskaya, E. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.07.038 · Cited by 104
D’Andrea, E., Hey, S. P., Ramirez, C. L., & Kesselheim, A. S. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2224 · Cited by 111
Fibrates Revisited: Potential Role in Cardiovascular Risk Reduction
Kim, N. H., & Kim, S. G. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0001 · Cited by 104
“In the early 2010s, the use of these nonstatin drugs was viewed skeptically, based on large-scale RCTs that showed no reduction in major cardiovascular events when added to statins [28-33].”
BackgroundHDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics
Vitali, C., Khetarpal, S. A., & Rader, D. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0940-0 · Cited by 101
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Annema, W., & von Eckardstein, A. (2016) · Translational Research · doi:10.1016/j.trsl.2016.02.008 · Cited by 94
Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
Parish, S., Hopewell, J. C., Hill, M. R., Marcovina, S., Valdes-Marquez, E., Haynes, R., Offer, A., Pedersen, T. R., Baigent, C., Collins, R., et al. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.117.001696 · Cited by 93
Goldstein, L. B., Toth, P. P., Dearborn-Tomazos, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., Woo, D., & on behalf of the American Heart Association Council on Arteriosclerosis, T. A. V. B. C. O. C. A. S. N. C. O. P. V. D. A. S. C. (2023) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 92
Evidence-based goals in LDL-C reduction
Soran, H., Dent, R., & Durrington, P. (2017) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1069-7 · Cited by 92
“Positive outcomes in OSLER, ODYSSEY and IMPROVE-IT studies are also significant in light of the failure of several other non-statin lipid lowering agents to demonstrate clinical benefit [20, 21].”
BackgroundIntracoronary Imaging, Cholesterol Efflux, and Transcriptomes After Intensive Statin Treatment
Kini, A. S., Vengrenyuk, Y., Shameer, K., Maehara, A., Meerarani, P., Yoshimura, T., Matsumura, M., Aquino, M. B., Haider, N., Johnson, K. W., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.10.029 · Cited by 93
“Decreased levels of high-density lipoprotein cholesterol (HDL-C) have been associated with increased cardiovascular risk in numerous epidemiological studies; however, randomized controlled trials with pharmacological intervention raising HDL-C have failed to reduce cardiovascular disease events (13,14).”
Lipoprotein(a) and Cardiovascular Disease in Chinese Population
Li, J., Ma, C.-S., Zhao, D. H., Yan, X.-W., Li, J., Ma, C., Zhao, D. H., Yan, X.-W., Ye, P., Chen, H., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.08.015 · Cited by 103
“Instead, the risk of severe adverse events was increased.(53,54) It remains unknown whether it is attributed to an insignificant increase of Lp(a) levels in the participants in the AIM-HIGH and HPS2-THRIVE studies.”
BackgroundDyslipidemia in diabetes mellitus and cardiovascular disease
Warraich, H. J., & Rana, J. S. (2017) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000120 · Cited by 103
Management of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 95
Cui, D., Yu, X., Guan, Q., Shen, Y., Liao, J., Liu, Y., & Su, Z. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00321-3 · Cited by 142
“In the statin era, however, large outcome trials show that adding niacin to intensive statin therapy, despite further improving the lipid profile, confers no additional cardiovascular risk reduction [227] and may even increase overall mortality [228]—an observation termed the “niacin paradox.”
The role of the lymphatic system in cholesterol transport
Huang, L., Elvington, A., & Randolph, G. J. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00182 · Cited by 104
Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages
Feingold, K. R., Moser, A., Shigenaga, J. K., & Grunfeld, C. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m050955 · Cited by 89
Safety and efficacy of ezetimibe: A meta-analysis
Savarese, G., De Ferrari, G. M., Rosano, G. M. C., & Perrone-Filardi, P. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.103 · Cited by 88
Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a review
White, C. R., Garber, D. W., & Anantharamaiah, G. M. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r051367 · Cited by 88
Tumurkhuu, G., Dagvadorj, J., Porritt, R. A., Crother, T. R., Shimada, K., Tarling, E. J., Erbay, E., Arditi, M., & Chen, S. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.027 · Cited by 97
“…beneficial effects, two recent randomized clinical studies failed to demonstrate an additional value for niacin therapy combined with statins in reducing cardiovascular events (HPS2-THRIVE Collaborative Group, 2013; HPS2THRIVE Collaborative Group et al., 2014; AIM-HIGH Investigators et al., 2011).”
Protective features of peripheral monocytes/macrophages in stroke
Gliem, M., Schwaninger, M., & Jander, S. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.11.004 · Cited by 88
HDL and type 2 diabetes: the chicken or the egg?
Xepapadaki, E., Nikdima, I., Sagiadinou, E. C., Zvintzou, E., & Kypreos, K. E. (2021) · Diabetologia · doi:10.1007/s00125-021-05509-0 · Cited by 94
Atherosclerotic plaque stabilization and regression: a review of clinical evidence
Sarraju, A., & Nissen, S. E. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00979-8 · Cited by 121
“Furthermore, in the placebo-controlled HPS2-THRIVE trial 76 of patients with vascular disease, the addition of extended-release niacin (laropiprant) to background statin therapy did not significantly decrease vascular events and led to an increase in adverse events.”
PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016
Banach, M., Jankowski, P., Jóźwiak, J., Cybulska, B., Windak, A., Guzik, T., Mamcarz, A., Broncel, M., & Tomasik, T. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.64712 · Cited by 86
“Similarly, HPS2-THRIVE has not found any additional clinical benefit of a treatment based on extended-release niacin with laropiprant (a compound inhibiting the synthesis of prostaglandin D2 which is responsible for skin redness and hot flushes) in combination with a statin [77].”
BackgroundResultHigh-Density Lipoprotein Function Measurement in Human Studies: Focus on Cholesterol Efflux Capacity
Rohatgi, A. K. (2015) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2015.05.004 · Cited by 95
Nutritional or pharmacological activation of HCA2 ameliorates neuroinflammation
Offermanns, S., & Schwaninger, M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.02.002 · Cited by 97
Handelsman, Y., & Lepor, N. E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008953 · Cited by 86
Statin-associated muscle symptoms—Managing the highly intolerant
Backes, J. M., Ruisinger, J. F., Gibson, C., & Moriarty, P. M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.01.006 · Cited by 92
Mason, R. P., Dawoud, H., Jacob, R. F., Sherratt, S. C. R., & Malinski, T. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.04.118 · Cited by 84
Dyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 98
Clinical approach to the inflammatory etiology of cardiovascular diseases
Ruscica, M., Corsini, A., Ferri, N., Banach, M., & Sirtori, C. R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104916 · Cited by 89
Lipoprotein(a) in atherosclerosis: from pathophysiology to clinical relevance and treatment options
Likozar, A. R., Zavrtanik, M., & Šebeštjen, M. (2020) · Annals of Medicine · doi:10.1080/07853890.2020.1775287 · Cited by 102
The Treatment of Disorders of Lipid Metabolism
Parhofer, K. G. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0261 · Cited by 105
Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials
Goldie, C., Taylor, A. J., Nguyen, P., McCoy, C., Zhao, X.-Q., & Preiss, D. (2016) · Heart · doi:10.1136/heartjnl-2015-308055 · Cited by 85
Effects of dyslipidaemia on monocyte production and function in cardiovascular disease
Rahman, M. S., Murphy, A. J., & Woollard, K. J. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.34 · Cited by 92
Qiu, C., Zhao, X., Zhou, Q., & Zhang, Z. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0604-5 · Cited by 93
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies
Cesaro, A., Schiavo, A., Moscarella, E., Coletta, S., Conte, M., Gragnano, F., Fimiani, F., Monda, E., Caiazza, M., Limongelli, G., et al. (2020) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001077 · Cited by 90
Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies
Kjeldsen, E. W., Thomassen, J. Q., Rasmussen, I. J., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab164 · Cited by 91
Existing and emerging strategies to lower Lipoprotein(a)
Schwartz, G. G., & Ballantyne, C. M. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.020 · Cited by 94
Wilson, D. P., Jacobson, T. A., Jones, P. H., Koschinsky, M. L., McNeal, C. J., Nordestgaard, B. G., & Orringer, C. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.007 · Cited by 97
“In addition, recent analysis from ODYSSEY OUTCOMES suggests that the Lp(a) reduction with alirocumab, independent of LDL-C, contributes to risk reduction.(71) As noted in section Laboratory Measurement of lipoprotein(a), niacin and hormone replacement treatment can reduce Lp(a).”
BackgroundMethodSafety Profile of Extended-Release Niacin in the AIM-HIGH Trial
Anderson, T. J., Boden, W. E., Desvigne-Nickens, P., Fleg, J. L., Kashyap, M. L., McBride, R., & Probstfield, J. L. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1311039 · Cited by 82
Sahebkar, A., Beccuti, G., Simental‐Mendía, L. E., Nobili, V., & Bo, S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.02.008 · Cited by 94
Ahmed, H. M., Miller, M. J., Nasir, K., McEvoy, J. W., Herrington, D. M., Blumenthal, R. S., & Blaha, M. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kwv305 · Cited by 88
LDL, HDL and endocrine-related cancer: From pathogenic mechanisms to therapies
Revilla, G., Cedó, L., Tondo, M., Moral, A., Pérez, J. I., Corcoy, R., Lerma, E., Fusté, V., Reddy, S. T., Blanco‐Vaca, F., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.012 · Cited by 89
Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps
Ference, B. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000247 · Cited by 82
Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study
Lenglet, A., Liabeuf, S., Esper, N. E., Brisset, S., Mansour, J., Lemaire‐Hurtel, A., Mary, A., Brazier, M., Kamel, S., Mentaverri, R., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw042 · Cited by 93
“In the NAM group, nausea, diarrhoea and thrombocytopenia were the most frequent AEs.”
BackgroundInfluentialStahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
HDL functionality in type 1 diabetes
Ganjali, S., Dallinga‐Thie, G. M., Simental‐Mendía, L. E., Banach, M., Pirro, M., & Sahebkar, A. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.018 · Cited by 90
Akioyamen, L. E., Genest, J. J., Chu, A., Inibhunu, H., Ko, D. T., & Tu, J. V. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.10.012 · Cited by 93
Current Role of Lipoprotein Apheresis
Thompson, G. R., & Parhofer, K. G. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0787-5 · Cited by 88
Triglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 81
Familial Hypercholesterolemia: a Review of the Natural History, Diagnosis, and Management
Najam, O., & Ray, K. K. (2015) · Cardiology and Therapy · doi:10.1007/s40119-015-0037-z · Cited by 98
Kallend, D. G., Reijers, J. A. A., Bellibas, S. E., Bobillier, A., Kempen, H. J. M., Burggraaf, J. L. I., Moerland, M., & Wijngaard, P. L. J. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv041 · Cited by 88
“Niacin effects multiple biomarkers including HDL-C and ApoA-1 but also failed to reduce CV events in combination with statin in two recent studies.(8,9) Interestingly, these drugs have limited effect on parameters of HDL function such as cholesterol efflux capacity.”
BackgroundEsan, O., & Wierzbicki, A. S. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 80
The Integration of Clinical Trials With the Practice of Medicine: Repairing a House Divided
Angus, D. C., Huang, A. J., Lewis, R. J., Abernethy, A. P., Califf, R. M., Landray, M., KASS, N. E., Bibbins-Domingo, K. B., Abbasi, A. B., Abebe, K. Z., et al. (2024) · JAMA · doi:10.1001/jama.2024.4088 · Cited by 95
Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome
Srikanth, S., & DEEDWANIA, P. C. (2016) · Current Hypertension Reports · doi:10.1007/s11906-016-0683-0 · Cited by 99
The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications
Wong, N. K. P., Nicholls, S. J., Tan, J. T. M., & Bursill, C. A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061680 · Cited by 81
“However, results from two large-scale clinical studies, AIM-HIGH [142] and HPS2-THRIVE [143], showed no significant benefit of adding niacin to statin therapy, with respect to the risk of major adverse cardiovascular events in both diabetic and non-diabetic patients.”
ResultFu, L., Tai, S., Sun, J., Zhang, N., Zhou, Y., Xing, Z., Wang, Y., & Zhou, S. (2022) · Diabetes Care · doi:10.2337/dc21-2511 · Cited by 77
HDL-cholesterol and cardiovascular disease: rethinking our approach
Siddiqi, H. K., Kiss, D., & Rader, D. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000211 · Cited by 77
Jackson, N., Atar, D., Borentain, M., Breithardt, G., van Eickels, M., Endres, M., Fraass, U., Friede, T., Hannachi, H., Janmohamed, S., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv213 · Cited by 76
McGarrah, R. W., Craig, D. M., Haynes, C., Dowdy, Z. E., Shah, S. H., & Kraus, W. E. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.012 · Cited by 77
Niacin: an old lipid drug in a new NAD+ dress
Romani, M., Hofer, D. C., Katsyuba, E., & Auwerx, J. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s092007 · Cited by 74
“major cardiovascular events; however, a significant improvement in HDL and TG levels remained (23, 24).”
BackgroundFamilial hypercholesterolemia: Review of diagnosis, screening, and treatment.
Turgeon, R. D., Barry, A. R., & Pearson, G. J. (2016) · Canadian Family Physician · Cited by 106
Budoff, M., Brent Muhlestein, J., Le, V. T., May, H. T., Roy, S., & Nelson, J. R. (2018) · Clinical Cardiology · doi:10.1002/clc.22856 · Cited by 73
Helgadóttir, A., Sulem, P., Þorgeirsson, G., Grétarsdóttir, S., Þorleifsson, G., Jensson, B. Ö., Arnadottir, G. A., Ólafsson, Í., Eyjolfsson, G. I., Sigurðardóttir, Ó., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy169 · Cited by 75
Karjalainen, M. K., Holmes, M. V., Wang, Q., Anufrieva, O., Kähönen, M., Lehtimäki, T., Havulinna, A. S., Kristiansson, K., Salomaa, V., Perola, M., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.002 · Cited by 73
Randomized Trials Versus Common Sense and Clinical Observation
Fanaroff, A. C., Califf, R. M., Harrington, R. A., Granger, C. B., McMurray, J. J. V., Patel, M. R., Bhatt, D. L., Windecker, S., Hernandez, A. F., Gibson, C. M., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.069 · Cited by 80
Liu, C., Chan, K. H., Lv, J., Lam, H. K. B., Newell, K., Meng, X., Liu, Y., Chen, R., Kartsonaki, C., Wright, N., et al. (2022) · Environmental Science & Technology · doi:10.1021/acs.est.2c03084 · Cited by 84
HDL Cholesterol and Non-Cardiovascular Disease: A Narrative Review
Kjeldsen, E. W., Nordestgaard, L. T., & Frikke‐Schmidt, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094547 · Cited by 80
Mason, R. P., Sherratt, S. C. R., & Jacob, R. F. (2016) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000379 · Cited by 72
Brinck, J. W., Thomas, A., Lauer, E., Jornayvaz, F. R., Brulhart‐Meynet, M., Prost, J., Pataky, Z., Löfgren, P., Hoffstedt, J., Eriksson, M., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.307049 · Cited by 76
Statin Intolerance: A Literature Review and Management Strategies
Saxon, D. R., & Eckel, R. H. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.009 · Cited by 80
Patel, S. B., Wyne, K. L., Afreen, S., Belalcazar, L. M., Bird, M. D., Coles, S., Marrs, J. C., Peng, C. C., Pulipati, V. P., Sultan, S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.016 · Cited by 85
Enhancing clinical evidence by proactively building quality into clinical trials
Meeker-O’Connell, A., Glessner, C., Behm, M., Mulinde, J., Roach, N., Sweeney, F., Tenaerts, P., & Landray, M. (2016) · Clinical Trials · doi:10.1177/1740774516643491 · Cited by 70
Khan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
Mendelian randomisation applied to drug development in cardiovascular disease: a review
Mokry, L. E., Ahmad, O., Forgetta, V., Thanassoulis, G., & Richards, J. B. (2015) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102438 · Cited by 68
Hendrani, A. D., Adesiyun, T., Quispe, R., Jones, S. R., Stone, N. J., Blumenthal, R. S., & Martin, S. S. (2016) · World Journal of Cardiology · doi:10.4330/wjc.v8.i2.201 · Cited by 85
Gordon, S. M., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.11.015 · Cited by 70
“However, as demonstrated by the more recent AIM-High (13) and HSP2-THRIVE (14) studies, there appears to be no benefit from niacin when added to a statin regimen.”
BackgroundManagement of dyslipidemia in adult solid organ transplant recipients
Warden, B. A., & Duell, P. B. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.011 · Cited by 79
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
Kastelein, J. J. P., Hsieh, A., Dicklin, M. R., Ditmarsch, M., & Davidson, M. H. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01184-1 · Cited by 68
Nonstatin Therapies for Management of Dyslipidemia: A Review
Sando, K. R., & Knight, M. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.001 · Cited by 73
“adding extended-release niacin in combination with laropiprant to statin therapy in those with previous vascular disease.(6) Laropiprant is an antagonist for the prostaglandin D2 receptor DP1, which can reduce the bothersome side effect of flushing commonly associated with niacin therapy.”
MethodLandray, M. J., & REVEAL Collaborative Group (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.021 · Cited by 68
HDL Functions—Current Status and Future Perspectives
Endo, Y., Fujita, M., & Ikewaki, K. (2023) · Biomolecules · doi:10.3390/biom13010105 · Cited by 84
Tardif, J., Rhainds, D., Brodeur, M. R., Zada, Y. F., Fouodjio, R., Provost, S., Boulé, M., Alem, S., Grégoire, J. C., L’Allier, P. L., et al. (2016) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.116.001405 · Cited by 73
Hypertriglyceridemia - Common Causes, Prevention and treatment Strategies
Rygiel, K. (2018) · Current Cardiology Reviews · doi:10.2174/1573403x14666180123165542 · Cited by 67
“Recently, two major CVD outcomes studies: AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes), and HPS2 THRIVE (The Heart Protection Study 2–Treatment of HDL to Reduce the Incidence of Vascular Events) using extended-release niacin (a vita…”
BackgroundUnravelling HDL—Looking beyond the Cholesterol Surface to the Quality Within
Kajani, S., Curley, S., & McGillicuddy, F. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071971 · Cited by 75
“These earlier studies conflict with more recent large clinical trials in 2011 and 2014, which found niacin treatment in combination with statin therapy did not provide clinical benefit over statins alone [20,21].”
BackgroundResultHDL cholesterol and ASCVD risk stratification: A debate
Barter, P. J., & Genest, J. J. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.001 · Cited by 72
Rethinking good cholesterol: a clinicians' guide to understanding HDL
Xiang, A. S., & Kingwell, B. A. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30003-8 · Cited by 75
HDL mimetic CER-001 targets atherosclerotic plaques in patients
Zheng, K. H., van der Valk, F. M., Smits, L. P., Sandberg, M., Dasseux, J., Baron, R., Barbaras, R., Keyserling, C., Coolen, B. F., Nederveen, A. J., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.05.038 · Cited by 74
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007–2014
Fan, W., Philip, S., Granowitz, C., Toth, P. P., & Wong, N. D. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00170-x · Cited by 66
Robinson, J. G., & Stone, N. J. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv182 · Cited by 70
Bhatia, H. S., & Wilkinson, M. J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206040 · Cited by 72
Ito, M. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.012 · Cited by 76
“In the Heart Protection Study 2 e Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), the addition of niacin to statin therapy did not reduce the risk of major cardiovascular events, but increased the risk of serious adverse events [57,58].”
Background
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.